Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Daily News

Eating More Ultraprocessed ‘Junk’ Food Linked to Higher CVD Risk

Michael O'Riordan

March 23, 2021

News Daily News

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

Shelley Wood

June 11, 2020

News Daily News

AHA Advisory Emphasizes Need for Food-System Innovation, and Proof That It Works

Yael L. Maxwell

May 02, 2019

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Daily News

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Michael O'Riordan

July 13, 2016

News Features

Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent

Michael O'Riordan

May 03, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

Advertisement

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Eating More Ultraprocessed ‘Junk’ Food Linked to Higher CVD Risk

Obesity’s Role in COVID-19 Deaths: Big Food, Slow Government to Blame?

AHA Advisory Emphasizes Need for Food-System Innovation, and Proof That It Works

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

AstraZeneca Strives to Block Generic Crestor as Observers Call Foul

Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content